Doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myeloma

Hani Hassoun, Lilian Reich, Virginia M. Klimek, Madhav Dhodapkar, Adam Cohen, Tarun Kewalramani, Rachel Zimman, Lisa Drake, Elyn R. Riedel, Cyrus V. Hedvat, Julie Teruya-Feldstein, Daniel A. Filippa, Martin Fleisher, Stephen D Nimer, Raymond L. Comenzo

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Among the drug combinations designed for the initial treatment of multiple myeloma, none has been unequivocally shown to be superior. However, a regimen leading to a high response rate and a low incidence of adverse events is highly desirable. We report the results of a phase II clinical trial involving 45 patients with Durie-Salmon stage II and III multiple myeloma. Doxorubicin and dexamethasone were given for 2 or 3 months followed by thalidomide and dexamethasone for 2 months (AD-TD regimen) with prophylactic antibiotics and daily aspirin (81 mg/d). Among the 42 patients whose response could be assessed, 38 responded to therapy (90.5%). The intent-to-treat response rate was 84.4% with seven complete responses (CR 15.5%), nine near complete responses (nCR 20.0%), and 22 partial responses (PR 48.9%). Two patients had stable disease (4.4%), and two progression of disease (4.4%). Normalization of the free light chain ratio after one or two cycles of treatment was highly predictive of achievement of CR or nCR. Patients tolerated the treatment well although five patients developed thromboembolic complications (11%). AD-TD administered with low dose aspirin for deep vein thrombosis prophylaxis was well tolerated and yielded a high response rate with minimal treatment-related morbidity.

Original languageEnglish
Pages (from-to)155-161
Number of pages7
JournalBritish Journal of Haematology
Volume132
Issue number2
DOIs
StatePublished - Jan 1 2006
Externally publishedYes

Fingerprint

Thalidomide
Multiple Myeloma
Doxorubicin
Dexamethasone
Aspirin
Therapeutics
Phase II Clinical Trials
Salmon
Drug Combinations
Venous Thrombosis
Disease Progression
Anti-Bacterial Agents
Morbidity
Light
Incidence

Keywords

  • Dexamethasone
  • Doxorubicin
  • Free light chain
  • Multiple myeloma
  • Thalidomide

ASJC Scopus subject areas

  • Hematology

Cite this

Doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myeloma. / Hassoun, Hani; Reich, Lilian; Klimek, Virginia M.; Dhodapkar, Madhav; Cohen, Adam; Kewalramani, Tarun; Zimman, Rachel; Drake, Lisa; Riedel, Elyn R.; Hedvat, Cyrus V.; Teruya-Feldstein, Julie; Filippa, Daniel A.; Fleisher, Martin; Nimer, Stephen D; Comenzo, Raymond L.

In: British Journal of Haematology, Vol. 132, No. 2, 01.01.2006, p. 155-161.

Research output: Contribution to journalArticle

Hassoun, H, Reich, L, Klimek, VM, Dhodapkar, M, Cohen, A, Kewalramani, T, Zimman, R, Drake, L, Riedel, ER, Hedvat, CV, Teruya-Feldstein, J, Filippa, DA, Fleisher, M, Nimer, SD & Comenzo, RL 2006, 'Doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myeloma', British Journal of Haematology, vol. 132, no. 2, pp. 155-161. https://doi.org/10.1111/j.1365-2141.2005.05848.x
Hassoun, Hani ; Reich, Lilian ; Klimek, Virginia M. ; Dhodapkar, Madhav ; Cohen, Adam ; Kewalramani, Tarun ; Zimman, Rachel ; Drake, Lisa ; Riedel, Elyn R. ; Hedvat, Cyrus V. ; Teruya-Feldstein, Julie ; Filippa, Daniel A. ; Fleisher, Martin ; Nimer, Stephen D ; Comenzo, Raymond L. / Doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myeloma. In: British Journal of Haematology. 2006 ; Vol. 132, No. 2. pp. 155-161.
@article{cebd29afb2354d8294648436666f5e1c,
title = "Doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myeloma",
abstract = "Among the drug combinations designed for the initial treatment of multiple myeloma, none has been unequivocally shown to be superior. However, a regimen leading to a high response rate and a low incidence of adverse events is highly desirable. We report the results of a phase II clinical trial involving 45 patients with Durie-Salmon stage II and III multiple myeloma. Doxorubicin and dexamethasone were given for 2 or 3 months followed by thalidomide and dexamethasone for 2 months (AD-TD regimen) with prophylactic antibiotics and daily aspirin (81 mg/d). Among the 42 patients whose response could be assessed, 38 responded to therapy (90.5{\%}). The intent-to-treat response rate was 84.4{\%} with seven complete responses (CR 15.5{\%}), nine near complete responses (nCR 20.0{\%}), and 22 partial responses (PR 48.9{\%}). Two patients had stable disease (4.4{\%}), and two progression of disease (4.4{\%}). Normalization of the free light chain ratio after one or two cycles of treatment was highly predictive of achievement of CR or nCR. Patients tolerated the treatment well although five patients developed thromboembolic complications (11{\%}). AD-TD administered with low dose aspirin for deep vein thrombosis prophylaxis was well tolerated and yielded a high response rate with minimal treatment-related morbidity.",
keywords = "Dexamethasone, Doxorubicin, Free light chain, Multiple myeloma, Thalidomide",
author = "Hani Hassoun and Lilian Reich and Klimek, {Virginia M.} and Madhav Dhodapkar and Adam Cohen and Tarun Kewalramani and Rachel Zimman and Lisa Drake and Riedel, {Elyn R.} and Hedvat, {Cyrus V.} and Julie Teruya-Feldstein and Filippa, {Daniel A.} and Martin Fleisher and Nimer, {Stephen D} and Comenzo, {Raymond L.}",
year = "2006",
month = "1",
day = "1",
doi = "10.1111/j.1365-2141.2005.05848.x",
language = "English",
volume = "132",
pages = "155--161",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myeloma

AU - Hassoun, Hani

AU - Reich, Lilian

AU - Klimek, Virginia M.

AU - Dhodapkar, Madhav

AU - Cohen, Adam

AU - Kewalramani, Tarun

AU - Zimman, Rachel

AU - Drake, Lisa

AU - Riedel, Elyn R.

AU - Hedvat, Cyrus V.

AU - Teruya-Feldstein, Julie

AU - Filippa, Daniel A.

AU - Fleisher, Martin

AU - Nimer, Stephen D

AU - Comenzo, Raymond L.

PY - 2006/1/1

Y1 - 2006/1/1

N2 - Among the drug combinations designed for the initial treatment of multiple myeloma, none has been unequivocally shown to be superior. However, a regimen leading to a high response rate and a low incidence of adverse events is highly desirable. We report the results of a phase II clinical trial involving 45 patients with Durie-Salmon stage II and III multiple myeloma. Doxorubicin and dexamethasone were given for 2 or 3 months followed by thalidomide and dexamethasone for 2 months (AD-TD regimen) with prophylactic antibiotics and daily aspirin (81 mg/d). Among the 42 patients whose response could be assessed, 38 responded to therapy (90.5%). The intent-to-treat response rate was 84.4% with seven complete responses (CR 15.5%), nine near complete responses (nCR 20.0%), and 22 partial responses (PR 48.9%). Two patients had stable disease (4.4%), and two progression of disease (4.4%). Normalization of the free light chain ratio after one or two cycles of treatment was highly predictive of achievement of CR or nCR. Patients tolerated the treatment well although five patients developed thromboembolic complications (11%). AD-TD administered with low dose aspirin for deep vein thrombosis prophylaxis was well tolerated and yielded a high response rate with minimal treatment-related morbidity.

AB - Among the drug combinations designed for the initial treatment of multiple myeloma, none has been unequivocally shown to be superior. However, a regimen leading to a high response rate and a low incidence of adverse events is highly desirable. We report the results of a phase II clinical trial involving 45 patients with Durie-Salmon stage II and III multiple myeloma. Doxorubicin and dexamethasone were given for 2 or 3 months followed by thalidomide and dexamethasone for 2 months (AD-TD regimen) with prophylactic antibiotics and daily aspirin (81 mg/d). Among the 42 patients whose response could be assessed, 38 responded to therapy (90.5%). The intent-to-treat response rate was 84.4% with seven complete responses (CR 15.5%), nine near complete responses (nCR 20.0%), and 22 partial responses (PR 48.9%). Two patients had stable disease (4.4%), and two progression of disease (4.4%). Normalization of the free light chain ratio after one or two cycles of treatment was highly predictive of achievement of CR or nCR. Patients tolerated the treatment well although five patients developed thromboembolic complications (11%). AD-TD administered with low dose aspirin for deep vein thrombosis prophylaxis was well tolerated and yielded a high response rate with minimal treatment-related morbidity.

KW - Dexamethasone

KW - Doxorubicin

KW - Free light chain

KW - Multiple myeloma

KW - Thalidomide

UR - http://www.scopus.com/inward/record.url?scp=33644823017&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644823017&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2141.2005.05848.x

DO - 10.1111/j.1365-2141.2005.05848.x

M3 - Article

VL - 132

SP - 155

EP - 161

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 2

ER -